Kelly Norsworthy, M.D.

Dr. Norsworthy is a Medical Oncologist and Hematologist, and serves as Scientific Liaison for Acute Myeloid Leukemia (AML) in the Division of Hematologic Malignancies 1 (DHM1), at the U.S. Food and Drug Administration (FDA). Dr. Norsworthy is a Clinical Reviewer on the leukemia team in DHM1 and Co-Chair of the Acute Leukemia/MDS focus group in FDA’s Oncology Center of Excellence. Her interests include differentiation therapies for the treatment of AML, the optimal diagnosis and management of differentiation syndrome, assessment of clinical trial endpoints for AML and relationship to overall survival, and development of novel therapeutics for AML, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms.

Dr. Norsworthy received her Bachelor of Science degree in Mathematics from the University of Maryland, College Park. Following graduation she worked as a biostatistician at the National Institutes of Health, Critical Care Medicine Department. Dr. Norsworthy received her M.D. from the University of Maryland School of Medicine, where she also completed residency training in Internal Medicine, and served as Chief Resident of the Internal Medicine training program. She completed her fellowship training in Hematology and Medical Oncology at Johns Hopkins Hospital.

Dr. Norsworthy remains clinically active, practicing inpatient leukemia part-time as an Adjunct Assistant Professor of Oncology at Johns Hopkins Hospital.